An Early Phase 1 interventional study of Cognitive Behavioral Treatment for Insomnia (CBT-I) and Trazodone in Insomnia, Insomnia Chronic and Insomnia, Primary, sponsored by Milton S. Hershey Medical Center. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Milton S. Hershey Medical Center · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders — 4 open to participants now, 4 under way, none of them phase 3. Trazodone · Sleep Initiation and Maintenance Disorders.
Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 1, and was the 9th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →4 of the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders are open now, in 2 countries. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18–80
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 65+
By country, each count listing its studies:
Trazodone: first FDA approval 1981 (DESYREL). What it is approved for, and how studies give it, is on its page →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 146 across the 12 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 5 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies testing trazodone in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06983080Centre hospitalier de l'Université de Montréal (CHUM)Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study) | 2027-07 |
| NCT06281756Milton S. Hershey Medical CenterCognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received placebo for 8 weeks.
Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) · Other: Placebo
Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received trazodone for 8 weeks.
Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) · Drug: Trazodone
Subjects will receive therapy for 8 weeks
Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
Non-remitting subjects will receive placebo for 8 weeks
Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I)
Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe
Time frame: 9 weeks
Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT)
Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe
Time frame: 9 weeks
Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT Treatment
Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe
Time frame: 35 weeks
Insomnia Severity Index (ISI) Score following CBT-I
0-28, with 0 being mild and 28 being severe
Time frame: 9 weeks
Polysomnography (PSG) Sleep efficiency following Cognitive Behavioral Therapy for Insomnia (CBT-I)
Polysomnography (PSG) Sleep efficiency measured as a percentage of time asleep during sleep study
Time frame: 9 weeks
Actigraphy Sleep efficiency following Cognitive Behavioral Therapy for Insomnia (CBT-I)
Actigraphy Sleep efficiency measured as estimated sleep time at home (2 week period)
Time frame: 9 weeks
Evening Cortisol levels following CBT-I
Cortisol levels measured in saliva collected following CBT-I
Time frame: 9 weeks
Insomnia Severity Index (ISI) Score following RCT
0-28, with 0 being mild and 28 being severe
Time frame: 9 weeks
PSG Total Sleep Time (TST) following RCT
PSG Total Sleep Time measured in minutes asleep during sleep study following RCT
Time frame: 9 weeks
Actigraphy Total Sleep Time (TST) following RCT
Actigraphy Total Sleep Time measured in minutes asleep during home study following RCT
Time frame: 9 weeks
Home Blood Pressure (HBP) Morning Systolic Blood Pressure (SBP)
Morning SBP Blood Pressure Readings measured at home (7 day period)
Time frame: 9 weeks
Home Blood Pressure (HBP) Morning Diastolic Blood Pressure (DBP)
Morning DBP Blood Pressure Readings measured at home (7 day period)
Time frame: 9 weeks
Evening Cortisol levels following RCT
Cortisol levels measured in saliva collected following RCT
Time frame: 9 weeks
Evening Cortisol levels 6 months following completion of CBT-I or RCT Treatment
Cortisol levels measured in saliva 6 months following CBT-I Or RCT Treatment
Time frame: 35 weeks
Plan to share: Yes — The investigators have extensive experience preparing data and documentation to be available for public. They agree to abide by the principles for sharing research resources described by the National Heart, Lung, Blood Institute (NHLBI). A copy of the data will be uploaded to the NHLBI Biologic Specimen and Data Repositories Information Coordinating Center (BioLINCC) repository. The datasets will not include any personal identifiers related to participants or clinical sites. Dates will be de-identified through a date-shifting algorithm to mask actual dates while maintaining a relation to the epoch in which events occurred. Data tables will be exported in comma-separated format, readable by statistical software. Variable dictionaries and code books, detailing variable description, format, value domain and labels, will be produced. Raw data files for polysomnogram/actigraphy/cortisol will also be made available, ensuring that data are linkable to study data and data are de-identified.
Supporting information: Study protocol, Analytic code
Time frame: Data collected for aim 1 (an observational study) and aim 2 (a randomized clinical trial) will be made available no more than 3 years after the completion of the last follow-up assessment. Data will be submitted to the Program Officer and uploaded to the NHLBI BioLINCC repository no later than 3 years after the end of clinical activity or 2 years after the main outcomes paper is published, whichever comes first.
Access criteria: NHLBI BioLINCC repository
Data sharing details ↗ · biolincc.nhlbi.nih.gov
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Nov 2027, 44 months after the start.
Of 39 phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 44 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Sleep Initiation and Maintenance Disorders →
Milton S. Hershey Medical Center →